Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.
| Revenue (TTM) | $4.01M |
| Gross Profit (TTM) | $-182.78M |
| EBITDA | $-226.35M |
| Operating Margin | -5699.00% |
| Return on Equity | -50.10% |
| Return on Assets | -29.70% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $5.20 |
| Price-to-Book | 4.17 |
| Price-to-Sales (TTM) | 610.96 |
| EV/Revenue | 466.61 |
| EV/EBITDA | -0.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $113.25M |
| Float | $108.33M |
| % Insiders | 6.30% |
| % Institutions | 102.23% |
Volatility is currently expanding